Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Artelo Biosciences Inc(ARTL)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for ARTL
09/25/2026: ARTL (1-star) is currently NOT-A-BUY. Pass it for now.
Artelo Biosciences is a clinical-stage biotechnology company focused on developing novel therapeutics that target the endocannabinoid system to treat cancer-related symptoms and inflammatory disorders. Its main strength lies in its specialized focus on niche therapeutic pathways, which offers a unique approach in the pharmaceutical landscape. The primary investment story centers on the potential of lead candidates like ART27.13 to address unmet clinical needs in oncology supportive care. Risks are significant, primarily due to the company's pre-revenue status, high capital intensity, and the binary outcomes associated with clinical trials. This stock is suited only for investors with a high risk tolerance who are monitoring clinical milestones.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The company offers potential upside from clinical success but carries extreme risk profile typical of pre-revenue biotech. |
| Momentum investor | Weak fit | Momentum is typically low without major clinical catalysts or positive regulatory developments. |
| Value investor | Weak fit | The company lacks earnings, cash flow, and assets to support a traditional value-based investment thesis. |
| Dividend investor | Weak fit | Artelo is an early-stage company that does not pay a dividend and reinvests all capital into R&D. |
| Low-risk investor | Weak fit | The extreme volatility and binary nature of clinical outcomes make this unsuitable for low-risk portfolios. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | The stock is susceptible to large price swings based on clinical trial news and capital market sentiment. |
| Valuation risk | High | Valuation is speculative and highly dependent on future clinical milestones that are not guaranteed. |
| Competition risk (Pharmaceutical) | High | Well-capitalized pharmaceutical giants dominate the therapeutic markets Artelo targets. |
| Business quality | Medium | The company is in the development phase, lacking established products or commercial revenue streams. |
| Dividend income | Low / none | The company does not generate the cash flow necessary to support dividend payments. |
| Execution risk | High | Success relies entirely on the successful navigation of complex, unpredictable, and expensive clinical trials. |
Price Behavior
Steep Decline
The stock price has dropped sharply with strong downward pressure.
Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type Stock | Historic Profit -57.39% | Avg. Invested days 28 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/25/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 2.49M USD | Price to earnings Ratio - | 1Y Target Price 18 |
Price to earnings Ratio - | 1Y Target Price 18 | ||
Volume (30-day avg) 986.8K shares | Beta -0.07 | 52 Weeks Range 3.45 - 161.73 | Updated Date 09/25/2026 |
52 Weeks Range 3.45 - 161.73 | Updated Date 09/25/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -101.07 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Drug Development | Clinical trial development for candidates like ART27.13 and ART26.12. | The company does not have products on the market and currently generates no significant revenue. |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -150.25K | Price to Sales(TTM) - |
Enterprise Value -150.25K | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 1.22 | Shares Outstanding 547.77K | Shares Floating 510.24K |
Shares Outstanding 547.77K | Shares Floating 510.24K | ||
Percent Insiders 0.11 | Percent Institutions 2.38 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Artelo Biosciences Inc
Exchange NASDAQ | Headquarters Solana Beach, CA, United States | ||
IPO Launch date 2017-11-14 | President, CEO, Secretary & Director Mr. Gregory D. Gorgas M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 7 | Website https://artelobio.com |
Full time employees 7 | Website https://artelobio.com | ||
Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. The company's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of cancer-related anorexia; and ART12.11, a cocrystal composition of cannabidiol and tetramethylpyrazine for the treatment anxiety, depression, post-traumatic stress disorder PTSD, epilepsy and insomnia, and other potential indications. It also offers ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders. The company was formerly known as Reactive Medical Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.